Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.

Researchers often ask a simple question: how do semaglutide and tirzepatide compare? Both are research peptides that many labs study side by side. This article looks at what each one is, what the published research shows when the two are compared, and how they differ. All material described here is for laboratory research use only and is not for human or animal use.

What is semaglutide?

Semaglutide is a peptide that acts as a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a natural gut hormone that helps the body manage blood sugar and appetite. A receptor agonist is a molecule that binds to a receptor and switches it on, so semaglutide acts on the GLP-1 receptor much like the natural hormone does. In research settings, semaglutide is studied as a single-target peptide because it works mainly through this one receptor. Under brand names, semaglutide is a well-known compound in published clinical research.

What is tirzepatide?

Tirzepatide is a peptide that acts on two receptors instead of one. It is a dual GIP and GLP-1 receptor agonist. You already know GLP-1. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also helps the body handle blood sugar. Because tirzepatide switches on both the GIP and the GLP-1 receptor, researchers call it a dual agonist. This two-target design is the main way tirzepatide differs from semaglutide.

Semaglutide vs tirzepatide: what the research shows

Several published trials have compared the two compounds head to head. In the SURPASS-2 trial, reported in the New England Journal of Medicine (Frias and colleagues, 2021), tirzepatide was compared with semaglutide once weekly in adults with type 2 diabetes. The authors reported that tirzepatide led to larger reductions in HbA1c (a marker of average blood sugar) and in body weight than semaglutide. A later study, SURMOUNT-5, also published in the New England Journal of Medicine (Aronne and colleagues, 2025), compared the two in adults with obesity who did not have diabetes. The authors reported that tirzepatide produced greater average weight loss and a larger reduction in waist size than semaglutide over the study period. These are findings from clinical research and are described here only as reported by the study authors. They are not claims about Dissolv Labs material, which is sold for laboratory research use only.

How the two research peptides differ

The clearest difference is the number of receptors each peptide targets. Semaglutide works through a single receptor, the GLP-1 receptor. Tirzepatide works through two, the GIP receptor and the GLP-1 receptor. Scientists often describe semaglutide as a single agonist and tirzepatide as a dual agonist. This mechanism difference is why the two are frequently studied together. Researchers want to understand how adding the second GIP target changes the results seen in the published trials above. Both remain active subjects of ongoing study.

Are semaglutide and tirzepatide FDA approved?

Yes. As finished prescription medicines under brand names, both compounds are approved by the U.S. Food and Drug Administration (FDA). Semaglutide was approved for chronic weight management under the brand name Wegovy on June 4, 2021. Tirzepatide was approved under the brand name Zepbound on November 8, 2023; the FDA describes it as a peptide that activates the GLP-1 and GIP receptors. These are plain regulatory facts. They apply to the branded prescription products, not to research chemicals. The material offered by Dissolv Labs is a research-use-only reference compound. It is not an approved drug and is not for human use. This is factual information, not medical or purchasing advice.

How researchers store and handle these peptides

Laboratories treat research peptides as sensitive materials that must be kept in good condition. In general, research suppliers describe these lyophilized (freeze-dried) peptides as stable when kept cool, dry, and away from light, with colder storage used for longer holding. Careful labeling and record keeping help a lab track what it has on hand. Nothing here is a direction for use in people or animals. These notes only describe how research materials are commonly stored and documented in a laboratory setting.

GLP-1 research materials at Dissolv Labs

Dissolv Labs supplies the following compounds as research-use-only reference materials for qualified laboratories:

• Semaglutide (research reference material)
• CagriSema 5mg plus 5mg (research reference material)
• Retatrutide (research reference material)

Frequently asked questions

Is semaglutide or tirzepatide a stronger research peptide?

The published head-to-head trials, SURPASS-2 and SURMOUNT-5, reported larger average effects for tirzepatide than for semaglutide. That is a summary of what those study authors reported, not a claim about any research chemical.

What is the main mechanism difference between them?

Semaglutide targets one receptor, GLP-1. Tirzepatide targets two, GIP and GLP-1. This single-target versus dual-target design is the core difference studied in the research.

Can Dissolv Labs material be used the same way as the branded drugs?

No. Dissolv Labs sells research-use-only reference material. It is not an approved medicine and is not for human or animal use. The FDA-approved brands are separate finished prescription products.

Where can researchers read the original studies?

The Sources list below links to the peer-reviewed trials and to FDA and reference records so researchers can read the primary findings for themselves.

The bottom line

Semaglutide is a single GLP-1 receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. In the published SURPASS-2 and SURMOUNT-5 trials, authors reported that tirzepatide produced larger average effects than semaglutide. Both are FDA-approved prescription medicines under brand names. The peptides offered by Dissolv Labs are research-use-only reference materials, not drugs, and are not for human or animal use.

Sources

• Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
• Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
• U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound / tirzepatide), 2023.
• Drugs.com. Wegovy (semaglutide) FDA Approval History.

Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.